{"id":6066,"date":"2023-08-24T16:01:25","date_gmt":"2023-08-24T20:01:25","guid":{"rendered":"https:\/\/bridgebio.local\/news\/auto-draft\/"},"modified":"2023-08-24T11:42:29","modified_gmt":"2023-08-24T15:42:29","slug":"bridgebio-pharma-to-present-detailed-results-from-the-phase-3-attribute-study-in-patients-with-transthyretin-amyloidosis-cardiomyopathy-attr-cm-at-european-society-of-cardiology-esc-congress-2023","status":"publish","type":"post","link":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-detailed-results-from-the-phase-3-attribute-study-in-patients-with-transthyretin-amyloidosis-cardiomyopathy-attr-cm-at-european-society-of-cardiology-esc-congress-2023\/","title":{"rendered":"BridgeBio Pharma to Present Detailed Results from the Phase 3 ATTRibute Study in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) at European Society of Cardiology (ESC) Congress 2023"},"content":{"rendered":"<p align=\"left\"><strong>PALO ALTO, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE)<\/strong> &#8212; BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\u201cBridgeBio\u201d or the \u201cCompany\u201d),\u00a0a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that detailed Phase 3 results from ATTRibute-CM, its study of acoramidis in transthyretin amyloid cardiomyopathy, or ATTR-CM, will be presented at the European Society of Cardiology (ESC) Congress 2023, taking place in Amsterdam, Netherlands on August 25 &#8211; 28, 2023. ATTRibute-CM was designed to study the efficacy and safety of acoramidis, an investigational, next-generation, orally-administered, highly potent, small molecule stabilizer of transthyretin (TTR).<\/p>\n<p>BridgeBio will host an investor call with members of the Company\u2019s leadership team as well as\u00a0Julian Gillmore, M.D., Ph.D., on Monday, August 28 at 8:30 am ET to discuss the results shared at the meeting.<\/p>\n<p>In addition to presenting the results from ATTRibute-CM, BridgeBio will also present a moderated poster on the observed near-complete TTR stabilization of acoramidis in patients with variant transthyretin amyloidosis, and will host a satellite symposium to discuss the evolving landscape of ATTR-CM.<\/p>\n<p><strong><u>Oral presentation &amp; moderated poster session details:<\/u><\/strong><\/p>\n<p><strong>ATTRibute-CM: Acoramidis (AG10) in patients with transthyretin amyloid cardiomyopathy<\/strong><br \/>\n<strong>Presenter:\u00a0<\/strong>Julian Gillmore, M.D., Ph.D., professor at University College London and head of University College London Centre for Amyloidosis and National Amyloidosis Centre research lead<br \/>\n<strong>Date\/ time:\u00a0<\/strong>Sunday, August 27 at 11:15 am CEST<br \/>\n<strong>Location:\u00a0<\/strong>ESC Stage, Amsterdam Auditorium, RAI Amsterdam<\/p>\n<p><strong>Acoramidis produces near-complete TTR stabilization in blood samples from patients with variant transthyretin amyloidosis that is greater than that achieved with tafamidis<\/strong><br \/>\n<strong>Presenter:\u00a0<\/strong>Alan Xian Ji, Ph.D., Senior Scientist, BridgeBio<br \/>\n<strong>Date\/time:\u00a0<\/strong>Saturday, August 26 at 5:15 pm CEST<br \/>\n<strong>Location:\u00a0<\/strong>Station 3, RAI Amsterdam<\/p>\n<p><strong><u>Satellite symposium details:<\/u><\/strong><\/p>\n<p><strong>Evolving Landscape in ATTR-CM: Clinical Practice and Emerging Treatments<\/strong><br \/>\n<strong>Chair:<\/strong>\u00a0Francesco Cappelli, M.D., medical director of cardiac surgery at the Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy<br \/>\n<strong>Speakers:<\/strong>\u00a0Marianna Fontana, M.D., director of the Cardiac Magnetic Resonance unit at the University College London and professor of cardiology and honorary consultant cardiologist at the National Amyloidosis Centre, Division of Medicine, University College London, Dr. Pablo Garcia-Pavia, head of the Inherited Cardiac Diseases and Heart Failure unit at the Department of Cardiology of Hospital Universitario Puerta de Hierro in Madrid, Spain; and Julian Gillmore, M.D., Ph.D., professor at University College London and head of University College London Centre for Amyloidosis and National Amyloidosis Centre research lead<br \/>\n<strong>Date\/time:\u00a0<\/strong>Monday, August 28 at 12:45 pm CEST<br \/>\n<strong>Location:\u00a0<\/strong>Stockholm Room, RAI Amsterdam<\/p>\n<p><strong>Webcast Information<\/strong><br \/>\nBridgeBio will host an investor call and simultaneous webcast with members of the company&#8217;s leadership team as well as Julian Gillmore, M.D., Ph.D., professor at University College London and head of University College London Centre for Amyloidosis and National Amyloidosis, to discuss the results presented at ESC 2023 for the ATTRibute-CM Phase 3 trial on Monday, August 28 at 8:30 am ET.\u00a0A link to the webcast may be accessed from the event calendar page of BridgeBio\u2019s website at\u00a0<strong><a href=\"https:\/\/investor.bridgebiodev.wpengine.com\/\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/investor.bridgebiodev.wpengine.com\/<\/a><\/strong>. A replay of the conference call and webcast will be archived on the Company\u2019s website and will be available for at least 30 days following the event.<\/p>\n<p><strong>About BridgeBio Pharma, Inc.<\/strong><br \/>\nBridgeBio Pharma Inc. (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio\u2019s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers, and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit\u00a0<a href=\"https:\/\/www.bridgebio.local\/\" target=\"_blank\" rel=\"nofollow noopener\"><strong>bridgebiodev.wpengine.com<\/strong><\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/www.linkedin.com\/company\/6824982\/admin\/\" target=\"_blank\" rel=\"nofollow noopener\"><strong>LinkedIn<\/strong><\/a>\u00a0and\u00a0<a href=\"https:\/\/twitter.com\/BridgeBioPharma\" target=\"_blank\" rel=\"nofollow noopener\"><strong>Twitter<\/strong><\/a>.<\/p>\n<p><strong>BridgeBio Media Contact:<\/strong><br \/>\nVikram Bali<br \/>\n<a href=\"mailto:contact@bridgebiodev.wpengine.com\" target=\"_blank\" rel=\"nofollow noopener\">contact@bridgebiodev.wpengine.com<\/a><br \/>\n(650)-789-8220<\/p>\n","protected":false},"excerpt":{"rendered":"<p>PALO ALTO, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) &#8212; BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\u201cBridgeBio\u201d or the \u201cCompany\u201d),\u00a0a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that detailed Phase 3 results from ATTRibute-CM, its study of acoramidis in transthyretin amyloid cardiomyopathy, or ATTR-CM, will be presented at the European Society of Cardiology [&hellip;]<\/p>\n","protected":false},"author":32,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[8],"tags":[],"class_list":["post-6066","post","type-post","status-publish","format-standard","hentry","category-news"],"acf":{"people":false,"external_link":"","presentation":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>BridgeBio Pharma to Present Detailed Results from the Phase 3 ATTRibute Study in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) at European Society of Cardiology (ESC) Congress 2023 - BridgeBio<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-detailed-results-from-the-phase-3-attribute-study-in-patients-with-transthyretin-amyloidosis-cardiomyopathy-attr-cm-at-european-society-of-cardiology-esc-congress-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BridgeBio Pharma to Present Detailed Results from the Phase 3 ATTRibute Study in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) at European Society of Cardiology (ESC) Congress 2023 - BridgeBio\" \/>\n<meta property=\"og:description\" content=\"PALO ALTO, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) &#8212; BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\u201cBridgeBio\u201d or the \u201cCompany\u201d),\u00a0a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that detailed Phase 3 results from ATTRibute-CM, its study of acoramidis in transthyretin amyloid cardiomyopathy, or ATTR-CM, will be presented at the European Society of Cardiology [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-detailed-results-from-the-phase-3-attribute-study-in-patients-with-transthyretin-amyloidosis-cardiomyopathy-attr-cm-at-european-society-of-cardiology-esc-congress-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"BridgeBio\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-24T20:01:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-24T15:42:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bridgebio.com\/wp-content\/uploads\/2019\/02\/BridgeBio_Share.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Holly Condon\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@BridgeBioPharma\" \/>\n<meta name=\"twitter:site\" content=\"@BridgeBioPharma\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Holly Condon\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-detailed-results-from-the-phase-3-attribute-study-in-patients-with-transthyretin-amyloidosis-cardiomyopathy-attr-cm-at-european-society-of-cardiology-esc-congress-2023\/\",\"url\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-detailed-results-from-the-phase-3-attribute-study-in-patients-with-transthyretin-amyloidosis-cardiomyopathy-attr-cm-at-european-society-of-cardiology-esc-congress-2023\/\",\"name\":\"BridgeBio Pharma to Present Detailed Results from the Phase 3 ATTRibute Study in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) at European Society of Cardiology (ESC) Congress 2023 - BridgeBio\",\"isPartOf\":{\"@id\":\"https:\/\/bridgebio.com\/#website\"},\"datePublished\":\"2023-08-24T20:01:25+00:00\",\"dateModified\":\"2023-08-24T15:42:29+00:00\",\"author\":{\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/e56e9128cd840531b0acdca992cb1fca\"},\"breadcrumb\":{\"@id\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-detailed-results-from-the-phase-3-attribute-study-in-patients-with-transthyretin-amyloidosis-cardiomyopathy-attr-cm-at-european-society-of-cardiology-esc-congress-2023\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-detailed-results-from-the-phase-3-attribute-study-in-patients-with-transthyretin-amyloidosis-cardiomyopathy-attr-cm-at-european-society-of-cardiology-esc-congress-2023\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-detailed-results-from-the-phase-3-attribute-study-in-patients-with-transthyretin-amyloidosis-cardiomyopathy-attr-cm-at-european-society-of-cardiology-esc-congress-2023\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/bridgebio.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BridgeBio Pharma to Present Detailed Results from the Phase 3 ATTRibute Study in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) at European Society of Cardiology (ESC) Congress 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/bridgebio.com\/#website\",\"url\":\"https:\/\/bridgebio.com\/\",\"name\":\"BridgeBio\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/bridgebio.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/e56e9128cd840531b0acdca992cb1fca\",\"name\":\"Holly Condon\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/4465d7631588f41599cacc7a8380e613?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/4465d7631588f41599cacc7a8380e613?s=96&d=mm&r=g\",\"caption\":\"Holly Condon\"},\"url\":\"https:\/\/bridgebio.com\/author\/hcondon\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BridgeBio Pharma to Present Detailed Results from the Phase 3 ATTRibute Study in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) at European Society of Cardiology (ESC) Congress 2023 - BridgeBio","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-detailed-results-from-the-phase-3-attribute-study-in-patients-with-transthyretin-amyloidosis-cardiomyopathy-attr-cm-at-european-society-of-cardiology-esc-congress-2023\/","og_locale":"en_US","og_type":"article","og_title":"BridgeBio Pharma to Present Detailed Results from the Phase 3 ATTRibute Study in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) at European Society of Cardiology (ESC) Congress 2023 - BridgeBio","og_description":"PALO ALTO, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) &#8212; BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\u201cBridgeBio\u201d or the \u201cCompany\u201d),\u00a0a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that detailed Phase 3 results from ATTRibute-CM, its study of acoramidis in transthyretin amyloid cardiomyopathy, or ATTR-CM, will be presented at the European Society of Cardiology [&hellip;]","og_url":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-detailed-results-from-the-phase-3-attribute-study-in-patients-with-transthyretin-amyloidosis-cardiomyopathy-attr-cm-at-european-society-of-cardiology-esc-congress-2023\/","og_site_name":"BridgeBio","article_published_time":"2023-08-24T20:01:25+00:00","article_modified_time":"2023-08-24T15:42:29+00:00","og_image":[{"width":1200,"height":600,"url":"https:\/\/bridgebio.com\/wp-content\/uploads\/2019\/02\/BridgeBio_Share.png","type":"image\/png"}],"author":"Holly Condon","twitter_card":"summary_large_image","twitter_creator":"@BridgeBioPharma","twitter_site":"@BridgeBioPharma","twitter_misc":{"Written by":"Holly Condon","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-detailed-results-from-the-phase-3-attribute-study-in-patients-with-transthyretin-amyloidosis-cardiomyopathy-attr-cm-at-european-society-of-cardiology-esc-congress-2023\/","url":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-detailed-results-from-the-phase-3-attribute-study-in-patients-with-transthyretin-amyloidosis-cardiomyopathy-attr-cm-at-european-society-of-cardiology-esc-congress-2023\/","name":"BridgeBio Pharma to Present Detailed Results from the Phase 3 ATTRibute Study in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) at European Society of Cardiology (ESC) Congress 2023 - BridgeBio","isPartOf":{"@id":"https:\/\/bridgebio.com\/#website"},"datePublished":"2023-08-24T20:01:25+00:00","dateModified":"2023-08-24T15:42:29+00:00","author":{"@id":"https:\/\/bridgebio.com\/#\/schema\/person\/e56e9128cd840531b0acdca992cb1fca"},"breadcrumb":{"@id":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-detailed-results-from-the-phase-3-attribute-study-in-patients-with-transthyretin-amyloidosis-cardiomyopathy-attr-cm-at-european-society-of-cardiology-esc-congress-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-detailed-results-from-the-phase-3-attribute-study-in-patients-with-transthyretin-amyloidosis-cardiomyopathy-attr-cm-at-european-society-of-cardiology-esc-congress-2023\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-detailed-results-from-the-phase-3-attribute-study-in-patients-with-transthyretin-amyloidosis-cardiomyopathy-attr-cm-at-european-society-of-cardiology-esc-congress-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bridgebio.com\/"},{"@type":"ListItem","position":2,"name":"BridgeBio Pharma to Present Detailed Results from the Phase 3 ATTRibute Study in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) at European Society of Cardiology (ESC) Congress 2023"}]},{"@type":"WebSite","@id":"https:\/\/bridgebio.com\/#website","url":"https:\/\/bridgebio.com\/","name":"BridgeBio","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/bridgebio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/bridgebio.com\/#\/schema\/person\/e56e9128cd840531b0acdca992cb1fca","name":"Holly Condon","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/bridgebio.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/4465d7631588f41599cacc7a8380e613?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4465d7631588f41599cacc7a8380e613?s=96&d=mm&r=g","caption":"Holly Condon"},"url":"https:\/\/bridgebio.com\/author\/hcondon\/"}]}},"_links":{"self":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts\/6066"}],"collection":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/comments?post=6066"}],"version-history":[{"count":0,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts\/6066\/revisions"}],"wp:attachment":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/media?parent=6066"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/categories?post=6066"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/tags?post=6066"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}